Preamble 1
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition ( 1 ) and in particular Article 13(3) thereof,
Whereas:
HAS ADOPTED THIS REGULATION:
recital 1recital 1
(1) In accordance with Council Directive 70/524/EEC ( 2 ) monensin sodium and narasin, were authorised as feed additives by, respectively, Commission Regulations (EC) No 1356/2004 ( 3 ) and (EC) No 1464/2004 ( 4 ) .
recital 2recital 2
(2) In accordance with Regulation (EC) No 1831/2003, endo-1,4-beta-mannanase and diclazuril were authorised as feed additives by, respectively, Commission Regulations (EC) No 786/2007 ( 5 ) , (EC) No 971/2008 ( 6 ) , (EU) No 1118/2010 ( 7 ) , (EU) No 169/2011 ( 8 ) and Commission Implementing Regulations (EU) No 888/2011 ( 9 ) and (EU) No 667/2013 ( 10 ) .
recital 3recital 3
(3) The holder of authorisation, Eli Lilly and Company Ltd, has submitted an application in accordance with Article 13(3) of Regulation (EC) No 1831/2003 proposing to change the name of the holder of the authorisation for the feed additives concerned.
recital 4recital 4
(4) The holder of authorisation claims that, with effect from 30 March 2018, Elanco GmbH, a division of Eli Lilly and Company Ltd owns the marketing rights for the additives concerned. The holder of authorisation has submitted relevant data supporting its request.
recital 5recital 5
(5) The proposed change of the terms of the authorisation is purely administrative in nature and does not entail a fresh assessment of the additives concerned. The European Food Safety Authority was informed of the application.
recital 6recital 6
(6) To allow Elanco GmbH to exploit its marketing rights it is necessary to change the terms of the authorisations concerned.
recital 7recital 7
(7) Regulations (EC) No 1356/2004, (EC) No 1464/2004, (EC) No 786/2007, (EC) No 971/2008, (EU) No 1118/2010, (EU) No 169/2011 and Implementing Regulations (EU) No 888/2011 and (EU) No 667/2013, should, therefore, be amended accordingly.
recital 8recital 8
(8) Since safety reasons do not require the immediate application of the amendments made by this Regulation, it is appropriate to allow a transitional period during which existing stocks may be used up.
recital 9recital 9
(9) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
Article 1Amendment to Regulation (EC) No 1356/2004
In the second column of the Annex to Regulation (EC) No 1356/2004, the words ‘Eli Lilly and Company Limited’ are replaced by the words ‘Elanco GmbH’.
Article 2Amendment to Regulation (EC) No 1464/2004
In the second column of the Annex to Regulation (EC) No 1464/2004, the words ‘Eli Lilly and Company Limited’ are replaced by the words ‘Elanco GmbH’.
Article 3Amendment to Regulation (EC) No 786/2007
In the second column of the Annex to Regulation (EC) No 786/2007, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 4Amendment to Regulation (EC) No 971/2008
In the second column of the Annex to Regulation (EC) No 971/2008, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 5Amendment to Regulation (EU) No 1118/2010
In the second column of the Annex to Regulation (EU) No 1118/2010, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 6Amendment to Regulation (EU) No 169/2011
In the second column of the Annex to Regulation (EU) No 169/2011, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 7Amendment to Regulation (EU) No 888/2011
In the second column of the Annex to Regulation (EU) No 888/2011 the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 8Amendment to Regulation (EU) No 667/2013
Regulation (EU) No 667/2013 is amended as follows:
(1) In the title, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’;
(2) In the second column of the Annex, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 9Transitional measure
Monensin sodium, narasin, endo-1,4-beta-mannanase, and diclazuril produced and labelled before the date of entry into force of this Regulation in accordance with the rules applicable before that date may continue to be placed on the market and used until stocks are exhausted.
Article 10Entry into force
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .